AIM
AUTL

AXA Investment Managers’s Autolus Therapeutics AUTL Stock Holding History

AXA Investment Managers’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$5.48M Buy
+3,361,156
New +$6.57M 0.01% 548

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AXA Investment Managers's AUTL Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Autolus Therapeutics (AUTL) in Q3 2025: 3,361,156 shares worth $5.48M. The stake represents 0.01% of the portfolio and ranks #548 among its holdings.

96 funds tracked by Wall St. Rank hold AUTL as of Q3 2025.

  • AXA Investment Managers held 3,361,156 shares of Autolus Therapeutics worth $5.48M as of Q3 2025.
  • Autolus Therapeutics was a new AXA Investment Managers position in Q3 2025.
  • Autolus Therapeutics made up 0.01% of AXA Investment Managers's portfolio in Q3 2025, its #548 holding.
  • 96 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.